FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine

테타누스 톡소이드, 감소된 디프테리아 톡소이드 및 세포외 백일해 백신의 연령 적응증 확대에 대한 FDA 승인

Published on
Journal: Morbidity and Mortality Weekly Report
[저자] Centers for Disease Control and Prevention (CDC)
[Category] 백일해, 파상풍,
Pubmed URL    DOI URL    
[Source] pubmed

On December 4, 2008, the Food and Drug Administration (FDA) approved an expanded age indication for the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) Boostrix (GlaxoSmithKline Biologicals, Rixensart, Belgium). Boostrix is now licensed for use in persons aged 10-64 years as a single-dose booster immunization; the vaccine initially was licensed for persons aged 10-18 years. This announcement summarizes the indications for use of Boostrix. Complete recommendations of the Advisory Committee on Immunization Practices (ACIP) for Tdap vaccines have been described previously.

All Keywords